Maintenance therapy in colon cancer

Cancer Treatment Reviews

Volumn 36, Issue SUPPL. 3, 2010, Pages

  Giuliani, F ^a   De Vita, F ^b   Colucci, G ^a   Pisconti, S ^c  

^a NATIONAL CANCER INSTITUTE GIOVANNI PAOLO II   (Italy)

^b UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^c Medical Oncology SS Annunziata Hospital Taranto   (Italy)

Author keywords

Colorectal cancer; Maintenance therapy

Indexed keywords

BEVACIZUMAB; CELECOXIB; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN; RALTITREXED;

ADD ON THERAPY; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER SURVIVAL; COLON CANCER; COLORECTAL CANCER; DRUG EFFICACY; HAND FOOT SYNDROME; HUMAN; MAINTENANCE THERAPY; MULTIPLE CYCLE TREATMENT; NEUROPATHY; OVERALL SURVIVAL; SURVIVAL RATE; TREATMENT DURATION; TREATMENT RESPONSE;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; COLONIC NEOPLASMS; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; HUMANS; ORGANOPLATINUM COMPOUNDS; SURVIVAL RATE;

EID: 78649756637     PISSN: 03057372     EISSN: 15321967     Source Type: Journal    
DOI: 10.1016/S0305-7372(10)70019-0     Document Type: Article

References (24)

1. de Gramont A, Bosset JF, Milan C, et al. Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: a French intergroup study. J Clin Oncol 1997, 15:808-815.
2. O'Neil BH, Goldberg RM Innovations in chemotherapy for metastatic colorectal cancer: an update of recent clinical trials. Oncologist 2008, 13:1074-1083.
3. Grothey A Oxaliplatin-safety profile: neurotoxicity. Sem Oncol 2003, 30(15):5-13.
4. Grothey A, Sargent D, Goldberg RM, et al. Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan and oxaliplatin in the course of treatment. J Clin Oncol 2004, 22:1209-1214.
5. Grothey A, Sargent D Overall survival of patients with advanced colorectal cancer correlates with availability of fluorouracil, irinotecan and oxaliplatin regardless of whether doublet or single-agent therapy is used first-line. J Clin Oncol 2005, 23:9441-9442.
6. Goldberg RM, Rothenberg ML, Van Cutsem E, et al. The continuum of care: a paradigm for the management of metastatic colorectal cancer. Oncologist 2007, 12:38-50.
7. Grothey A. Optimized treatment of metastatic colorectal cancer. Educational book ASCO 2009, pp. 209-11.
8. Hejna M, Kornek GV, Raderer M, et al. Reinduction therapy with the same cytostatic regimen in patients with advanced colorectal cancer. Br J Cancer 1998, 78(6):760-764.
9. Maughan TS, James RD, Kerr DJ, et al. Comparison of intermittent and continuous palliative chemotherapy for advanced colorectal cancer: a multicenter randomized trial. Lancet 2003, 361:457-464.
10. Chibaudel B, Maindrault-Goebel F, Mineur L, et al. Can chemotherapy be discontinued in unresectable metastatic colorectal cancer? The GERCOR OPTIMOX2 study. J Clin Oncol 2009, 27:5727-5733.
11. Adams R, Wilson R, Seymur M, et al. Intermittent versus continuous oxaliplatin-based combination chemotherapy in patients with advanced colorectal cancer: a randomized non-inferiority trial (MRC COIN). Eur J Cancer 2009, 7(2). Abst 15LBA.
12. Andre T, Tournigand C, Mineur L, et al. Phase II study of an optimized 5-fluoro-uracil-oxaliplatin strategy (OPTIMOX2) with celecoxib in metastatic colorectal cancer: a GERCOR study. Ann Oncol 2007, 18:77-81.
13. Alexopoulos CG, Kotsori AA Continuous versus intermittent chemotherapy in metastatic colorectal cancer. J Clin Oncol 2006, 24:18S. (Abst 3582).
14. Labianca R, Floriani I, Cortesi E, et al. Alternating versus continuous 'Folfiri'in advanced colorectal cancer (ACC): a randomized 'GISCAD'trial. J Clin Oncol 2006, 24:18S. (Abst 3505).
15. Tournigand C, Cervantes A, Figer A, et al. OPTIMOX1: a randomized study of Folfox4 or Folfox7 with oxaliplatin in a stop-and-go fashion in advanced colorectal cancer. A GERCOR study. J Clin Oncol 2006, 24:394-400.
16. Hochster HS Stop-and-go: yes or not?. J Clin Oncol 2009, 27:5677-5679.
17. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil and leucovorin for metastatic colorectal cancer. N Engl J Med 2004, 350:2335-2342.
18. Giantonio BJ, Catalano PJ, Meropol NJ, et al. Bevacizumab in combination with oxaliplatin, fluorouracil and leucovorin (Folfox4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol 2007, 25:1539-1544.
19. Saltz LB, Clarke S, Diaz-Rubio E, et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol 2008, 26:2013-2019.
20. Grothey A, Hart L, Rowland K, et al. Intermittent oxaliplatin (oxali) administration and time-to-treatment failure (TTF) in metastatic colorectal cancer (mCRC): final results of the phase III CONcePT trial. J Clin Oncol 2008, 26:15S. (Abst 4010).
21. Tabernero J, Aranda E, Gomez A, et al. Phase III study of first-line Xelox plus bevacizumab (Bev) for 6 cycles followed by Xelox plus Bev or single agent (s/a) Bev as maintenance therapy in patients (pts) with metastatic colorectal cancer (mCRC): the MACRO trial (Spanish Coooperative Group for the Treatment of Digestive Tumours (TTD). J Clin Oncol 2010, 28:15S. (Abst 3501).
22. Giuliani F, De Vita F, Addeo R, et al. Folfiri plus bevacizumab as first-line treatment in metastatic colorectal cancer: a phase II study by the Gruppo Oncologico dell'Italia Meridionale (prot. 2601) (in press).
23. Munoz A, Pericay C, Llorente A, et al. Phase II study of bevacizumab plus oxaliplatin plus capecitabine followed by bevacizumab plus erlotinib as firstline treatment of metastatic colorectal cancer (mCRC). J Clin Oncol 2010, 28:15S. (abstr. 3539).
24. Tournigand C, Gamson B, Scheithauer W, et al. mFolfox-bevacizumab or Xelox-bevacizumab then bevacizumab (B) alone or with erlotinib (E) in first-line treatment of patients with metastatic colorectal cancer (mCRC): interim safety analysis of DREAM study. J Clin Oncol 2009, 27:15S. (Abst 4077).